WO2004100892A3 - Nouveaux facteurs de croissance des fibroblastes et procedes pour les utiliser - Google Patents

Nouveaux facteurs de croissance des fibroblastes et procedes pour les utiliser Download PDF

Info

Publication number
WO2004100892A3
WO2004100892A3 PCT/US2004/014623 US2004014623W WO2004100892A3 WO 2004100892 A3 WO2004100892 A3 WO 2004100892A3 US 2004014623 W US2004014623 W US 2004014623W WO 2004100892 A3 WO2004100892 A3 WO 2004100892A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fibroblast growth
growth factors
novel fibroblast
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/014623
Other languages
English (en)
Other versions
WO2004100892A2 (fr
Inventor
Jeffrey Peterson
Paul Sciore
Peter Mezes
Henri Lichenstein
Michael Jeffers
William Larochelle
Marie Ruiz-Martinez
Galina Chernaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to AU2004238332A priority Critical patent/AU2004238332A1/en
Priority to CA002525107A priority patent/CA2525107A1/fr
Priority to JP2006532928A priority patent/JP2007516223A/ja
Priority to EP04751821A priority patent/EP1626696A2/fr
Publication of WO2004100892A2 publication Critical patent/WO2004100892A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004100892A3 publication Critical patent/WO2004100892A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour traiter diverses pathologies, notamment un accident vasculaire cérébral, une cicatrisation et des maladies articulaires (par ex. l'ostéoarthrose et la polyarthrite rhumatoïde). Cette invention concerne plus particulièrement des compositions comprenant un membre de la famille des facteurs de croissance des fibroblastes, FGF-CX (également connu sous la dénomination CG53135-05 ou FGF-20), ses polypeptides associés, des acides nucléiques codant de tels polypeptides, ainsi que leurs utilisations pour traiter une pathologie, notamment un accident vasculaire cérébral, une cicatrisation et des maladies articulaires (par ex. l'ostéoarthrose et la polyarthrite rhumatoïde).
PCT/US2004/014623 2003-05-09 2004-05-10 Nouveaux facteurs de croissance des fibroblastes et procedes pour les utiliser Ceased WO2004100892A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2004238332A AU2004238332A1 (en) 2003-05-09 2004-05-10 Novel fibroblast growth factors and methods of use thereof
CA002525107A CA2525107A1 (fr) 2003-05-09 2004-05-10 Nouveaux facteurs de croissance des fibroblastes et procedes pour les utiliser
JP2006532928A JP2007516223A (ja) 2003-05-09 2004-05-10 新規線維芽細胞成長因子及びその使用方法
EP04751821A EP1626696A2 (fr) 2003-05-09 2004-05-10 Nouveaux facteurs de croissance des fibroblastes et procedes pour les utiliser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46935303P 2003-05-09 2003-05-09
US60/469,353 2003-05-09

Publications (2)

Publication Number Publication Date
WO2004100892A2 WO2004100892A2 (fr) 2004-11-25
WO2004100892A3 true WO2004100892A3 (fr) 2008-04-10

Family

ID=33452279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014623 Ceased WO2004100892A2 (fr) 2003-05-09 2004-05-10 Nouveaux facteurs de croissance des fibroblastes et procedes pour les utiliser

Country Status (5)

Country Link
EP (1) EP1626696A2 (fr)
JP (1) JP2007516223A (fr)
AU (1) AU2004238332A1 (fr)
CA (1) CA2525107A1 (fr)
WO (1) WO2004100892A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
WO2002002625A2 (fr) * 2000-07-03 2002-01-10 Curagen Corporation Nouveaux facteurs de croissance des fibroblastes et acides nucleiques codant pour ces memes facteurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056885B1 (en) * 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US20060094647A1 (en) * 2000-11-06 2006-05-04 Jeffers Michael E Treatment of inflammatory bowel disease using growth factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
WO2002002625A2 (fr) * 2000-07-03 2002-01-10 Curagen Corporation Nouveaux facteurs de croissance des fibroblastes et acides nucleiques codant pour ces memes facteurs

Also Published As

Publication number Publication date
AU2004238332A2 (en) 2004-11-25
WO2004100892A2 (fr) 2004-11-25
EP1626696A2 (fr) 2006-02-22
CA2525107A1 (fr) 2004-11-25
JP2007516223A (ja) 2007-06-21
AU2004238332A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2002008284A3 (fr) Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
WO2002000690A3 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
WO2002014368A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002006339A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2005019256A3 (fr) Muteines de lipocaline lacrymale
WO2003037932A3 (fr) Polypeptides du facteur vii de coagulation humain
WO1999053040A3 (fr) Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne
WO2002055705A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2002050277A3 (fr) Proteines et acides nucleiques codant pour celles-ci
WO2002057453A3 (fr) Polypeptides et acides nucleiques codant ces derniers
WO2002068649A3 (fr) Proteines et acides nucleiques les codant
WO2005046587A3 (fr) Preparation et composition de proteines d'inhibiteur inter-alpha a partir du plasma humain, a usage therapeutique
WO2002068652A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2001090155A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002098917A3 (fr) Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
WO2004076614A3 (fr) Sequences d'acide nucleique humaines issues de carcinomes de la prostate
WO2001081578A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2005024006A3 (fr) Polypeptides du facteur vii de coagulation
WO2004094651A3 (fr) Nouveaux polypeptides humains codes par des polynucleotides
WO2002016599A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2001066747A8 (fr) Nouvelles proteines et acides nucleiques codant lesdites proteines
WO2007087053A3 (fr) Compositions à base de variantes de bmp-7, procédés et utilisations
WO2003022998A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation correspondantes
WO2002099116A8 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation
WO2002083841A3 (fr) Polypeptides therapeutiques, acides nucleiques les codant, et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2525107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006532928

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2004238332

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004751821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004238332

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004751821

Country of ref document: EP